来自北美关键 alfapump® 研究 (POSEIDON) 的 Roll-In Cohort 的数据被

StephenW

来自北美关键 alfapump® 研究 (POSEIDON) 的 Roll-In Cohort 的数据被选为 AASLD The Liver Meeting® 的海报展示

发布时间：2022 年 10 月 21 日

Florence Wong 博士于 11 月 6 日星期日在华盛顿特区发表的演讲：
“自动低流量腹水泵可改善肝硬化和复发性腹水患者的腹水控制和生活质量”

比利时根特 – 2022 年 10 月 21 日 – Sequana Medical NV（布鲁塞尔泛欧证券交易所：SEQUA，“公司”或“Sequana Medical”）是治疗肝病、心力衰竭和癌症的耐药性液体超负荷的先驱，今天宣布来自 POSEIDON1 的 Roll-In Cohort（其北美关键 alfapump 研究）的数据已被选为美国肝病研究协会 (AASLD) 肝脏会议的海报展示，该会议于 4 月 4 日在华盛顿特区举行至 2022 年 11 月 8 日。

海报题为“自动低流量腹水泵改善肝硬化和复发性腹水患者的腹水控制和生活质量”，将于 11 月 6 日星期日由多伦多大学 FAASLD 医学博士 Florence Wong 博士在 1美国东部时间下午 00-2:00。摘要将在肝脏会议开始之前在 AASLD 网站上发布。

完整的演讲列表可以在这里找到：https://www.aasld.org/the-liver-meeting

Sequana Medical 管理层将出席 The Liver Meeting 并随时准备会面。

获取更多资讯，请联系：

Sequana 医疗
谎言凡内斯特
投资者关系总监
电子邮件：[email protected]
电话：+32 498 05 35 79

最佳战略沟通
尼克·巴斯汀，丽贝卡·努南
电子邮件：[email protected]
电话：+44 (0) 20 3922 0900

StephenW

Data from Roll-In Cohort of North American pivotal alfapump® study (POSEIDON) selected for poster presentation at AASLD The Liver Meeting®

Published: Oct 21, 2022

Presentation by Dr. Florence Wong on Sunday November 6thin Washington, DC:
“An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent Ascites”

Ghent, Belgium – 21 October 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces that data from the Roll-In Cohort of POSEIDON1, its North American pivotal alfapump study, have been selected for a poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place in Washington, DC from 4 to 8 November 2022.

The poster, titled “An Automatic Low Flow Ascites Pump Improves Ascites Control and Quality of Life In Patients with Cirrhosis and Recurrent Ascites”, will be presented by Dr. Florence Wong, MD, FAASLD, University of Toronto on Sunday, November 6th between 1:00-2:00pm EST. The abstract will become available on the AASLD website prior to the start of The Liver Meeting.

A full list of presentations can be found here: https://www.aasld.org/the-liver-meeting

Sequana Medical management will attend The Liver Meeting and is available to meet.

For more information, please contact:

Sequana Medical
Lies Vanneste
Director Investor Relations
Email: [email protected]
Tel: +32 498 05 35 79

Optimum Strategic Communications
Nick Bastin, Rebecca Noonan
Email: [email protected]
Tel: +44 (0) 20 3922 0900